연구성과로 돌아가기
2024 연구자 정보 (51 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Phillips, Ankur J. (Phillips, AJ) |
JU Agri Sci Pvt Ltd, R&D Biol, Ind Area, Bulandshahr, Uttar Pradesh, India |
|
|
[JCR상위 1.7] Skin protection from solar ultraviolet radiation using natural compounds: a review | SCIE | 1.7 | CHEMISTRY, MULTIDISCIPLINARY;ENVIRONMENTAL SCIENCES;ENGINEERING, ENVIRONMENTAL | ankit.verma@mail.huji.ac.il;alessandra.zanoletti@unibs.it;2021321530@knu.ac.kr;adelodun.b@unilorin.edu.ng;kumarpankajgkv@gmail.com;foajibade@futa.edu.ng;lsilva8@cuc.edu.co;ankurphillips245@gmail.com;tkarthees@gmail.com;elza.bontempi@unibs.it;ashish.dwivedi1@iitr.res.in; | ||
|
Ren, Zhenggang (Ren, ZG) |
Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Rha, Sun Young (Rha, SY) |
Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea |
|
0000-0002-2512-4531 Rha, Sun Young |
[JCR상위 1.7] Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma [JCR상위 7.0] Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial [JCR상위 1.0] Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY |
SCIE | 1.0 |
ONCOLOGY MULTIDISCIPLINARY SCIENCES GASTROENTEROLOGY & HEPATOLOGY |
hyosong77@yuhs.ac; msasako2010@yahoo.co.jp; ykkang@amc.seoul.kr; |
||
|
Rodrigues, Darren (Rodrigues, D) |
|
|
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) |
SCIE | 1.7 | ONCOLOGY | ||||
|
Ryoo, Baek-Yeol (Ryoo, BY) |
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Ryu, Jai Min (Ryu, JM) |
Sungkyunkwan Univ, Samsung Med Ctr, Dept Surg, Div Breast Surg,Sch Med, Seoul, South Korea Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) [JCR상위 61.2] Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial [JCR상위 0.2] Minimal Access vs Conventional Nipple-Sparing Mastectomy |
SCIE | 0.2 |
ONCOLOGY SURGERY |
likeicetea@hanmail.net;hblee.md@snu.ac.kr; imgenius@yuhs.ac;j.lee@knu.ac.kr; |
||
|
Ryu, Seung Wan (Ryu, SW) |
Keimyung Univ, Dept Surg, Dongsan Med Ctr, Daegu, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Sangro, Bruno (Sangro, B) |
Clin Univ Navarra, Liver Unit, Pamplona, Spain Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain CIBEREHD, Pamplona, Spain Univ Navarra Clin, Liver Unit, Pamplona, Spain Univ Navarra Clin, HPB Oncol Area, Pamplona, Spain |
AFW-4106-2022 Sangro, Bruno |
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Shin, Eunju (Shin, E) |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY | ||||
|
Shin, Jisoo (Shin, J) |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY | ||||
|
Shin, Seon-Hi (Shin, SH) |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY | ||||
|
Shin, Su-Jin (Shin, SJ) |
Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Pathol, Seoul, South Korea |
I-6927-2019 KIM, JIN |
|
[JCR상위 1.7] Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma [JCR상위 7.0] Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
SCIE | 1.7 |
ONCOLOGY MULTIDISCIPLINARY SCIENCES |
hyosong77@yuhs.ac; | ||
|
Sim, Nam Suk (Sim, NS) |
|
|
[JCR상위 1.7] Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma | SCIE | 1.7 | ONCOLOGY | ||||
|
Sohn, Joohyuk (Sohn, J) |
제1저자 |
Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea Yonsei Univ, Div Med Oncol, Coll Med, Seoul, South Korea Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea |
|
0000-0002-2303-2764 Sohn, Joohyuk |
[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. [JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) |
SCIE | 1.7 | ONCOLOGY | oncolee@ewha.ac.kr;yhparkhmo@skku.edu; | |
|
Son, Gyung Mo (Son, GM) |
W-2979-2019 Son, Gyung |
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY |
페이지 이동: